Table 3.
Mutation analysis in adeno‐ versus squamous cell non‐small cell lung cancer
| Adenocarcinomas (n = 59) | |||||
|---|---|---|---|---|---|
| All | Lepidic | Acinar | Papillary | Solid | |
| Mutation | (n = 59) | (n = 8) | (n = 26) | (n = 6) | (n = 19) |
| AKT1 | 0 | 0 | 0 | 0 | 0 |
| BRAF | 1 (1.7%) | 0 | 0 | 0 | 1 (5.3%) |
| EGFR | 6 (10.2%) | 2 (25%) | 4 (15.4%) | 0 | 0 |
| ERBB2 | 0 | 0 | 0 | 0 | 0 |
| IDH1 | 0 | 0 | 0 | 0 | 0 |
| IDH2 | 1 (1.7%) | 0 | 0 | 0 | 1 (5.3%) |
| JAK2 | 0 (0%) | 0 | 0 | 0 | 0 |
| KIT | 2 (4.3%) | 0 | 2 (7.7%) | 0 | 0 |
| KRAS | 21 (35.6%) | 4 (50%) | 10 (38.5%) | 1 (17%) | 6 (31.6%) |
| PDGFRA | 1 (1.7%) | 0 | 0 | 0 | 1 (5.3%) |
| PIK3CA | 0 | 0 | 0 | 0 | 0 |
| TP53 | 42 (71.2%) | 5 (62.5%) | 19 (73.1%) | 3 (50%) | 15 (78.9%) |
| Mutation | Squamous cell | P‐value | |||
| carcinoma (n = 38) | AC versus SCC | ||||
| AKT1 | 1 (2.6%) | ||||
| BRAF | 0 | ||||
| EGFR | 0 | P = 0.042 | |||
| ERBB2 | 0 | ||||
| IDH1 | 1 (2.6%) | ||||
| IDH2 | 1 (2.6%) | ||||
| JAK2 | 0 | ||||
| KIT | 1 (2.6%) | ||||
| KRAS | 2 (5.3%) | P = 0.001 | |||
| PDGFRA | 0 | ||||
| PIK3CA | 4 (10.5%) | P = 0.011 | |||
| TP53 | 37 (97.4%) | P = 0.001 | |||
AKT, protein kinase B; BRAF, v‐raf murine sarcoma viral oncogene homolog B; EGFR, epidermal growth factor receptor; IDH, isocitrate dehydrogenase; KIT, KIT proto‐oncogene receptor tyrosine kinase; KRAS, Kirsten rat sarcoma viral oncogene; PDGFRA, platelet‐derived growth factor receptor A; PIK3CA, gene encoding for the phosphatidylinositol 3‐kinase (PI3K) catalytic subunit; TP53: transformation‐related protein 53.